IMMU-132 & TROP2: Molecular Mechanisms and Cancer Treatment

IMMU-132, also known as sacituzumab govitecan, is an antibody-drug conjugate that targets the TROP2 protein. TROP2 (Trophoblast Cell Surface Antigen 2) is a cell surface protein that is overexpressed in various types of cancer, including breast, lung, and colorectal cancer.

IMMU-132 works by specifically binding to the TROP2 protein on cancer cells. The antibody component of IMMU-132 recognizes and attaches to the TROP2 protein, while the drug component (SN-38) is released into the cancer cell, leading to cell death.

In terms of molecular aspects, IMMU-132 binding to TROP2 on cancer cells can have several effects:

1. Internalization: Once IMMU-132 binds to TROP2, the complex is internalized by the cancer cell through receptor-mediated endocytosis. This internalization process allows the drug component to enter the cancer cell.

2. Drug release: After internalization, the drug component (SN-38) is released from the antibody-drug conjugate within the cancer cell. SN-38 is a topoisomerase I inhibitor, which inhibits DNA replication and leads to cell death.

3. Downregulation of TROP2: The binding of IMMU-132 to TROP2 can also lead to downregulation of TROP2 expression on the cancer cell surface. This downregulation can occur through various mechanisms, such as receptor internalization and degradation, reduced protein synthesis, or altered gene expression.

Overall, IMMU-132 affects TROP2 expression in molecular aspects by specifically binding to the TROP2 protein, internalizing into the cancer cell, releasing the drug component, and potentially downregulating TROP2 expression. These molecular events contribute to the anti-cancer effects of IMMU-132 in TROP2-overexpressing cancers.